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Available online 2 June 2011Recently we described a co-culture model of periodontal ligament (PDL) fibroblasts and SCC-25
lingual squamous carcinoma cells, which resulted in conversion of normal fibroblasts into
carcinoma-associated fibroblasts (CAFs), and in epithelial–mesenchymal transition (EMT) of SCC-
25 cells. We have found a constitutive high interleukin-1β (IL1-β) expression in SCC-25 cells in
normal and in co-cultured conditions. In our hypothesis a constitutive IL1-β expression in SCC-25
regulates gene expression in fibroblasts during co-culture. Co-cultures were performed between
PDL fibroblasts and SCC-25 cells with and without dexamethasone (DEX) treatment; IL1-β
processing was investigated in SCC-25 cells, tumor cells and PDL fibroblasts were treated with
IL1-β. IL1-β signaling was investigated by western blot and immunocytochemistry. IL1-β-
regulated genes were analyzed by real-time qPCR.
SCC-25 cells produced 16 kD active IL1-β, its receptor was upregulated in PDL fibroblasts during co-
culture, which induced phosphorylation of interleukin-1 receptor-associated kinase-1 (IRAK-1), and
nuclear translocalization of NFκBα. Several genes, including interferon regulatory factor 1 (IRF1)
interleukin-6 (IL-6) and prostaglandin-endoperoxide synthase 2 (COX-2) were induced in CAFs
during co-culture. The most enhanced induction was found for IL-6 and COX-2. Treatment of PDL
fibroblasts with IL1-β reproduced a time- and dose-dependent upregulation of IL1-receptor, IL-6 and
COX-2. A further proof was achieved by DEX inhibition for IL1-β-stimulated IL-6 and COX-2 gene
expression. Constitutive expression of IL1-β in the tumor cells leads to IL1-β-stimulated gene
expression changes in tumor-associated fibroblasts, which are involved in tumor progression.
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from a number of invasive human carcinomas, which are
competent to promote the growth of carcinoma cells [1]. A
functional property of CAFs is the sustained expression of
stromal derived factor 1 (SDF-1) [2,3], which plays a central
role in the local invasion of cancer [4]. In tumor cells, stroma
microenvironment induces an epithelial–mesenchymal transi-
tion (EMT), which is considered as a major biological process
in epithelial tumor invasion [5], progression and metastasis.
During this process invasive tumor cells tend to lose their
epithelial antigens [6], their epithelial cell polarity and
morphology, and acquire mesenchymal and stemness-related
features [7–9]. EMT is implicated in the progression of
primary tumors toward metastases [3]. In our recent report
we described a co-culture model of periodontal ligament
(PDL) fibroblasts and SCC-25 oral squamous carcinoma cells,
which resulted in conversion of normal fibroblasts into CAFs.
In the same model EMT occurred in SCC-25 cells, representing
its key-events: detection of snail-expression, increase of
vimentin production and significant reduction of E-cadherin
expression [3].We have identified CAFs as a major source of
BDNF (brain-derived neurotrophic factor) [3], which specifi-
cally binds to tropomyosin-like kinase B receptor (TrkB) and
drives EMT in the tumor cells [10]. This finding described a
novel mechanism for the involvement of the BDNF-TrkB-axis
in tumor progression, as it was the first clear demonstration,
which showed that conversion of oral fibroblasts into CAFs
and EMT in oral carcinoma cells are simultaneous, coordinated
events [3]. There are scarce reports about the regulation of
BDNF-gene-expression. The role of the inflammatory cytokines
in induction of BDNF-expression was described in astrocytes
[11]. TNF-α represented a potential factor for regulating the
induction of CAFs. TNF-α-expression was also significant in
both oral fibroblasts and in carcinoma cells; moreover, in
EMT-carcinoma cells its expression significantly increased [3].
A role of TNF-α in regulating EMT has been extensively
reported recently [12,13]. In addition, in our previous report
we described a constitutive high interleukin-1β (IL1-β)
expression in SCC-25 cells in normal and in co-cultured
conditions [3].
Interleukin 1 (IL1-β) is a proteinwith several biological activities
regulating host defense and immune responses. Its' cDNA encodes a
precursor polypeptide of 269 amino acids (30.747 kD), which is
initially translated as a precursor molecule and subsequently
processed into the 15–20 kD protein associated with IL-1 activity
[14]. Several genes are regulated by IL1-β including interferon
regulatory factor 1 (IRF1), interleukin-6 (IL-6), plasminogen-
activator inhibitor-1 (PAI1) and prostaglandin-endoperoxide
synthase 2 (COX-2) [15].
In our hypothesis human oral SCC cells produce processed,
active IL1-β; CAFs react on this cytokine and produce IL1-β-
regulated gene products. In this study we prove this hypothesis
and provide evidences that oral squamous carcinoma cells, via
IL1-β-gene expression, protein synthesis and procession induce
the expression of IL1-β-regulated genes in CAFs, and initiate the
release of major tumor prognostic factors of head and neck
oncology into the stroma.Materials and methods
Cell lines
PDL fibroblasts were routinely cultured in DMEM-low glucose
(PAA, Linz, Austria) supplemented with 10% fetal bovine serum
(FBS) (PAA), 2 mM L-glutamine, 100 units/ml penicillin, and
100 μg/ml streptomycin. SCC-25 cells were purchased from the
German Collection of Microorganisms and cell cultures (Braun-
schweig, Germany), and were routinely cultured in DMEM/F12
(PAA, Linz, Austria) supplemented with 10% FBS (PAA), 2 mM L-
glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and
100 μg/ml streptomycin [3].
Co-culture
Co-culture between SCC-25 cells and PDL fibroblasts was detailed
described before [3].
Briefly, PDL fibroblasts were plated in DMEM-low-glucose/10%
FBS at 104/ml on cell culture inserts containing a 0.45 μm plastic
membrane filter, and SCC-25 cells in DMEM/F12/10% FBS at 4×104/
ml in wells of six-well plate (Greiner, Kremsmünster, Austria). Each
experimental system contained controls, which were plated in the
sameway. After 48 h the cell culture insertswith the fibroblastswere
put together with the wells containing SCC-25 cells. The direct
contact of the cells was prevented by a 0.45 μm plastic membrane,
but there was a continuous communication between the upper and
the lower cells. The cells in the filter received DMEM-low-
glucose/10% FBS, the cells underneath in the wells received DMEM/
F12/10% FBS. In the controls the fibroblasts or SCC-25 cells were
omitted, but the corresponding medium was always given to the
inserts or to the wells. The medium in the co-cultures and in the
controls was changed after 3 days. After 7 days co-culture the
experiment was finished, the cells in the inserts and in the wells
were used for RNA isolation, or for protein fractionation [3]. In some
experiments the co-cultured cells were treated with 10−6 mol/L
dexamethasone (Sigma, Vienna, Austria) as previously reported [15].
In theco-culture system in somecases 1.5 cm indiameter iBidiDishes
(Gerasdorf, Austria) were placed into the 6-well plates under the
inserts and PDL fibroblasts were plated into them in 10% fetal bovine
serum- (FBS-) supplemented-DMEM-low glucose (PAA, Pasching,
Austria) at 104/ml [3]. SCC-25 cells were plated into the cell culture
inserts (Greiner) in DMEM/F12/ — 10% FBS (PAA) at 4×104/ml [3].
The co-culture was timely performed as referenced [3]. The SCC-25
cells in the inserts were prepared for protein isolation, the iBidi
Dishes were used for NFκBα immunocytochemistry.
Treatment of PDLs with IL1-β
2×105/ml PDLs were plated in 10% FBS-supplemented-DMEM-low-
glucose (PAA, Pasching, Austria) in 10 cm culture plates (Unilab,
Innsbruck, Austria). After 48 h, medium was replaced by 0.3% FBS-
containing-DMEM. Cells were treated with IL1-β at 0.015–1.5 ng/ml
concentration range for 4, 8 and 24 h as described before [16].
RNA extraction, reverse transcription and PCR
Total RNA was isolated and reverse transcribed from control and
co-cultured cells as described before [3,17]. All used PCR primers
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(IL-6) [19], Interferon regulatory factor 1 (IRF1) [20], Plasmino-
gen-activator inhibitor-1 (PAI1) [21], and Prostaglandin-endoper-
oxide synthase 2 (COX-2) [22]. β-actin functioned well as
housekeeping gene [3], and did not show significant changes in
co-culture conditions compared to controls. The relative gene
expression was calculated as previously reported [17].
Protein fractionation, immunoprecipitation and
western blot
Cells after co-culture and controls were scraped into 500 μl
extraction buffer/well or/insert, non-nuclear and nuclear protein
fractionation were performed as described previously [23]. Non-
nuclear protein fractions were subjected to protein concentration
measurement [23], and 16 μg proteins were used for western blots
with mouse monoclonal antibodies for NFκBα (Cat. No: sc-8008)
or for Interleukin-1 receptor-associated kinase-1 (IRAK-1) (Cat.
No: sc-5288) or with rabbit polyclonal antibody for phospho-IRAK
(Cat No: sc-130197). All these primary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and used at
1 μg/ml final concentration. Nuclear protein fractions were also
subjected to protein concentration measurement, and 16 μg
proteins were used for western blot of NFκBα (Santa Cruz). Blots
were processed in a western blot protocol previously detailed
described [3].
Serum-reduced (0.3%) DMEM/F12 medium was used for 4 h
incubation of SCC-25 cells plated at 105 cells/plate in 10 cm in
diameter tissue culture dishes (Unilab) 48 h after plating. The
conditioned medium was collected and the cells were lysed in an
immunoprecipitation buffer (25 mM Tris, 150 mM NaCl, pH:7.5,
proteinase inhibitors added as one tablet of Complete Mini/10 ml
buffer (Roche, Mannheim, Germany)) following the instructions of
the provider of Protein A/G agarose (Cat. No: 20421, Pierce,
Rockford, IL, USA). In the conditioned cell supernatants and in the
cell lysates immunoprecipitation was performed using a rabbit
polyclonal antibody for IL1-β (Cat. No. PAI-28380, Pierce) accord-
ing to the instruction of the provider of Protein A/G agarose.
Immunoprecipitated fractions of the conditioned cell supernatants
and cell lysates were taken into 50 μl 1×Laemmli SDS-containing
gel loading buffer, were subjected to vertical polyacrylamide gel
electrophoresis (18% gels) [24], and were trans-blotted to
nitrocellulose membranes. The membranes were reacted with
polyclonal antibody for IL1-β (Pierce) (1:200 dilution), and were
further processed in the western blot protocol as described before
[3]. Non-binding fractions and 1 μg pure rabbit IgG (Pierce) were
used as controls for the immunoprecipitation.
If quantitative analysis was required, density of the detected
bands was measured by the Image J software [3,17].
Immunocytochemistry and confocal microscopy
IBidi Dishes with control and co-cultured PDLs were used for
NFκBα immunocytochemistry after fixation with methanol for
20 mins at −20 °C. Blocking was performed with PBS-buffer
containing 5% bovine serum albumin (BSA) (Roth, Karlsruhe,
Germany) and 1% normal donkey serum (Jackson Immu-
noscience, West Grove, PA, USA) for 2 h at room temperature,
the primary antibody of mouse monoclonal anti-NFκBα (Santa
Cruz) was used at 1:40 dilution (5 μg/ml) at 4 °C, overnight.Isotype matching control IgG (Santa Cruz) was used in control
reactions; this IgG did not show detectable reactivity. Anti-mouse
Alexa Fluor 647- (Invitrogen, Carlsbad, CA, USA) coupled
secondary donkey immunoglobulin was used at 1:1200 final
dilution in PBS-buffer containing 1% BSA for signal detection by
2 h at room temperature incubation. Finally, iBidi Dishes were
covered with DAPI-containing Vectashield (Vector Laboratories,
Burlingame, CA, USA) and observed in a Zeiss LSM 510 (Jena,
Germany) confocal microscope.
Statistical analysis
Each experiment was performed in three independent sets
containing at least three biological repeats/sets, altogether 9
repeats were performed. The relative gene-expression results
were tested for normal distribution by D'Agostino & Pearson
omnibus normality test using the Graphpad Prism 4.03 (Graphpad
Software Inc). Significance of changes in co-culture vs. controls
was tested by non-parametric tests (Mann-Whitney) and Stu-
dents' t-tests depending on the distribution of the data, using
Graphpad Prism. The independent experimental sets were then
compared for reproducibility. Only reproducible significant
changes were considered as “significant”. Significance was
declared by the standard p<0.05 level.Results
Synthesis and procession of IL1-β in SCC-25 oral squamous
carcinoma cells
Recently we reported a constitutive IL1-β mRNA expression not
only in SCC-25 oral squamous carcinoma cells in co-culture with
PDL fibroblasts, but also in control cells [3]. In the next step, we
investigated the IL1-β protein synthesis and processing in the
conditioned supernatant and cell lysate of SCC-25 cells by
immunoprecipitation. The active IL1-β protein was expected by
15–20 kD [14], which was found both in the conditioned
supernatant and the cell lysate of SCC-25 (Fig. 1A arrow).
IL1-β signaling in co-cultured fibroblasts
At first, the IL1 receptor gene expression was investigated in
control and co-cultured SCC-25 cells and fibroblasts, in order to
elucidate, which cells might react on the high expressed and
processed IL1-β protein of SCC-25 cells. SCC-25 possess low levels
of IL1 receptor, which does not change during co-culture
(p=0.18; Fig. 1B). PDL fibroblasts express 4.56-times higher
levels of IL1 receptor mRNA, which significantly (p<10−4) further
increases 3.37-times in co-culture with SCC-25 cells (Fig. 1B).
Following binding of IL1-β protein to the receptor a key event is
the phosphorylation of Interleukin-1 receptor-associated kinase 1
(IRAK1). Phosphorylated IRAK1 was also detected in control PDL
fibroblasts, but IRAK phosphorylation was significantly induced
(p=0.02) in co-cultured fibroblasts (Figs. 2A and C).
After several steps and activation of multiple pathways a
further, non-exclusive, but major event in IL1-β signaling is the
nuclear translocalization of the p65 c-Rel fragment of the
transcription factor NFκBα. In co-cultured fibroblasts a significant
increase of nuclear p65 was observed (p<0.05) (Figs. 2 B and D).
Fig. 1 – A) Detection of IL1-βprotein in cell lysate and supernatant
of SCC-25 cells by combined immunoprecipitation and western
blot. 1–2: supernatantofSCC-25cells, 3–4: cell lysateof SCC-25cells,
non-antibody-binding fraction of SCC-25 supernatant (5) and cell
lysate (6), and1 μg anti-IL1-β IgG (7). Arrow represents the active,
processed 16 kD IL1-β detectable both in the supernatant and cell
lysate of SCC-25 cells. B) Normalized gene expression of IL-1
receptor in control and co-cultured fibroblasts and SCC-25 cells. In
co-cultured fibroblasts IL-1R gene expression significantly
increases.
Fig. 2 – IL1-β signaling in co-cultured fibroblasts. A) Detection of
IRAK and phosphorylated-IRAK (p-IRAK) protein in cytoplasma
extract of control (1–3) and co-cultured (4–6) fibroblasts. B)
DetectionofNFκBαprotein in cytoplasma andnuclear extracts of
control (1–3) and co-cultured (4–6) fibroblasts. C) Densitometry
of p-IRAK bands normalized to IRAK bands in cytoplasma
extracts of control and co-cultured fibroblasts. D) Densitometry
of NFκBα protein in cytoplasma and nuclear extracts of control
and co-cultured fibroblasts normalized to protein loading
controls.
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nuclear localization of p65 NFκBα (Figs. 3 A-B).
Analysis of IL1-β-regulated genes in co-cultured fibroblasts
Following the investigation of the IL1-β signaling, the expression
of known IL1-β− regulated genes was analyzed in co-cultured
fibroblasts vs. control cells. IRF1, IL-6 and COX-2 showed
significant upregulation in co-cultured fibroblasts compared to
control cells (p<10−4), while PAI gene expression did not change
significantly (p=0.1). IRF1 increased 3-times, IL-6 60-times and
COX-2: 222-times. The most prominent responsive genes for
the presence of SCC-25 tumor cells in fibroblasts were: IL-6 and
COX-2.
IL1-β-treatment of fibroblasts and SCC-25 cells
PDL fibroblasts were treated with IL1-β following a previously
described treatment schedule [16]. The gene expression of IL-1
receptor and of the previously found induced genes: IRF1, IL-6 and
COX-2 was investigated. IL-1 receptor, IL-6 and COX-2 showed
time- and dose-dependent upregulation, which was statistically
significant (p<0.05; Fig. 4) in the case of IL-6 and COX-2. In the
same treatment schedule 24 h treatment of IL1-β at 1.5 ng/mlinduced a significant upregulation (p<10−3) of COX-2 and of IL-1
receptor (p=0.023) in SCC-25 cells. IL-6 was not significantly
regulated by IL1-β (p>0.05) in SCC-25 cells.
Dexamethasone treatment of the co-culture
IL-6 and COX-2 two extensively regulated genes in PDL fibroblasts
upon IL1-β-treatment and in co-culture with SCC-25 were
investigated in the same co-culture conditions as described before
[3], and some of the co-cultures were treated with 10−6 mol/L
dexamethasone (DEX) [15]. The gene expression of IL-6 decreased
to 30.85% (Fig. 5A), of COX-2 (Fig. 5B) to 0.3% in DEX-treated co-
cultured fibroblasts of that of only co-cultured fibroblasts.Discussion
Inflammation is commonly associated with cancer, and the
upregulation of proinflammatory mediators has been observed
Fig. 3 –NFκBα (red) immunocytochemistry in control (A) and co-cultured fibroblasts (B). Arrows indicate nuclear localization (blue
DAPI-detection) of NFκBα (red) reaction. Panels are represented separately and merged. Bars: 100 μm.
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activation of a cascade of proinflammatory cytokines and functions
as an important autocrine and/or paracrine factor in coordinating
expression of a repertoire of cytokines in HNSCC [26]. Authors
found that IL-1β caused the downregulation of E-cadherin
expression and upregulation of COX-2 expression, showing a
direct relationship between EMT occurring in HNSCC tumor cells
and inflammatory cytokines [26]. In our recent report we
described a co-culture model of periodontal ligament (PDL)
fibroblasts and SCC-25 oral squamous carcinoma cells, which
resulted in conversion of CAFs from normal fibroblasts, and in EMT
in SCC-25 cells [3]. In addition, we have identified CAFs as a major
source of BDNF (brain-derived neurotrophic factor) [3], which
specifically binds to tropomyosin-like kinase B receptor (TrkB) and
drives EMT in the tumor cells [10]. The role of the inflammatory
cytokines in induction of BDNF-expression was described before
[11]. We also reported a constitutive interleukin-1β (IL1-β)
expression in SCC-25 cells in normal and in co-cultured condi-
tions [3]. In our hypothesis a constitutive IL1-β expression in SCC-
25 regulates genes in fibroblasts during co-culture. We have
proven this regulation step by step. SCC-25 cells produce active,
processed IL1-β. PDL fibroblasts possess receptor for IL1-β, and its
expression is increased 4.56-times in the presence of SCC-25
tumor cells. IL1-β receptor expression in fibroblasts, especially in
CAFs represents a major option in coordination of fibroblast and
tumor behavior. A key event in IL1-β signaling, the phosphoryla-
tion of IRAK, occurred in co-cultured fibroblasts, which has lead to
nuclear translocation of NFκBα, and finally to induction of several
genes, including BDNF, IRF1, IL-6 and COX-2. The most enhanced
induction was found for IL-6 and COX-2 (Fig. 6). Treatment of PDL
fibroblasts with IL1-β reproduced a time- and dose-dependent
upregulation of IL1-receptor, IL-6 and COX-2. A further proof was
achieved by DEX inhibition of IL1-β stimulated gene expression,
which was an adaptation of a previously published experimental
system of human fibroblast-like synoviocytes [15]. Interestingly,not only the IL1-β stimulated IL-6 expression, but also the
stimulation of COX-2 was inhibited by DEX. All these proofs
underline the main finding of this work that, HNSCC-tumor cells
produce active IL1-β and stimulate extensive gene expression of
IL-6 and of COX-2 in carcinoma-associated fibroblasts. All findings
in this study were achieved by complementary methodology using
RNA methods, western blots, immunoprecipitation and immuno-
cytochemistry. IL1-β treatment and DEX-inhibition of IL1-β-
stimulated gene expression were based on peer-reviewed and
published references [15,16].
Both of the extensively regulated genes in CAFs, IL-6 and COX-
2, play major roles in the progression of HNSCC. Interestingly, SCC-
25 tumor cells might also respond to external IL1-βwith increased
COX-2 expression. Nevertheless, IL1-β treated tumor cells have no
significant contribution to IL-6 levels.
Evidences were reported that IL-6 can directly influence cell
proliferation and the invasion potential as the first step of tumor
metastasis, in fact, IL-6 increased the invasion potential of several
HNSCC cell lines [27]. Sensitive detection technologies have been
developed [28] in order to measure serum IL-6, which is the only
serum marker that significantly improved outcome prediction.
Higher levels of IL-6 were associated with a higher second primary
cancer incidence [29]. Further studies revealed that serum IL-6
could be a valuable biomarker for predicting recurrence and
overall survival among HNSCC patients. Using IL-6 as a biomarker
for recurrence and survival may allow for earlier identification and
treatment of disease relapse [30]. From a clinical point of view it is
highly important that increased IL-6 levels were found in cachectic
patients, whose quality of life was substantially reduced [31].
Based on experimental results in IL-6 gene knock-out mice it was
suggested that, IL-6 secretion and cancer cachexia syndrome may
be involved in the defense mechanism against tumor progression
[32].
Similarly to IL-6 also COX-2 plays a major role in the
progression of HNSCC. The overexpression of COX-2 is a frequent
Fig. 5 – Expression of IL-6: (A) and COX-2 (B), in control, co-
cultured and Dexamethason (DEX)-treated, co-cultured fibro-
blasts. IL-6 decreased to 30.85% (A), COX-2 (B) to 0.3% in DEX-
treated co-cultured fibroblasts of that of only co-cultured
fibroblasts.
Fig. 4 – Expression of IL1-β-regulated genes in PDL fibroblasts
after IL1-β-tratment (IL1 receptor: A, IRF1: B, IL-6: C, COX-2:D).
IL1 receptor: (A), IL-6 (C) and COX-2 (D), showed time- and
dose-dependent regulation.
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and non-steroidal anti-inflammatory drugs, which are potent
inhibitors of COX-1 and COX-2, exert chemopreventive effects on
HNSCC cancer development. COX-2 promotes the release of the
pro-inflammatory mediator prostaglandin E2 (PGE2), which acts
on its cell surface G protein-coupled receptors EP1, EP2, EP3, and
EP4. PGE2 produced in the tumor microenvironment by theoverexpression of COX-2 in tumor and stroma cells may promote
the growth of HNSCC cells in an autocrine and paracrine fashion by
acting on PGE2 receptors that are widely expressed in most HNSCC
cancer cells [33].
COX-2 expression is closely correlated to VEGF expression and
to tumor vascularisation. Patients with COX-2 tumor overexpres-
sion and with higher PgE (2) tumor levels have significantly
shorter overall survival estimates [34].Conclusion
In our workwe have provided further evidences that production of
proinflammatory cytokines in HNSCC, which is associated with
increased tumor growth or metastasis, is promoted by the
interaction of neoplastic cells with factors and cells in the host
environment. As it was previously reported, the expression of
these cytokines by HNSCC cells occurs independently of T and B
lymphocyte-mediated immunity [35]. The expression of some
proinflammatory cytokines is detectable in the tumor cells and the
one of other cytokines in the tumor-associated fibroblasts, and is
promoted by tumor–host interactions [35]. Inflammatory regula-
tory pathways are represented as a major therapeutic target in the
HNSCC oncology.Acknowledgments
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Fig. 6 – Schematic summary of the main regulation mechanism
of IL1β in CAFs. SCC-25 cells produce active, processed 16 kD
IL1-β. PDL fibroblasts possess receptor for IL1-β, which leads to
the phosphorylation of IRAK, and to subsequent nuclear
translocation of NFκBα, and finally to induction of several
genes, including BDNF, IRF1, IL-6 and COX-2.
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